Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Evolus stock

EOLS
US30052C1071
A2JDYX

Price

9.87
Today +/-
+0.39
Today %
+4.11 %

Evolus stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Evolus stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Evolus stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Evolus stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Evolus's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Evolus Stock Price History

DateEvolus Price
1/14/20259.87 undefined
1/14/20259.47 undefined
1/13/20259.80 undefined
1/10/202510.00 undefined
1/8/202510.21 undefined
1/7/202510.74 undefined
1/6/202511.00 undefined
1/3/202511.53 undefined
1/2/202511.11 undefined
12/31/202411.04 undefined
12/30/202410.89 undefined
12/27/202411.09 undefined
12/26/202411.35 undefined
12/24/202410.85 undefined
12/23/202410.84 undefined
12/20/202410.89 undefined
12/19/202410.87 undefined
12/18/202411.08 undefined
12/17/202411.73 undefined

Evolus Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Evolus, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Evolus from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Evolus’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Evolus. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Evolus’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Evolus’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Evolus’s growth potential.

Evolus Revenue, EBIT and net profit per share

DateEvolus RevenueEvolus EBITEvolus Net Income
2029e841.15 M undefined198.06 M undefined149.84 M undefined
2028e702.36 M undefined131.48 M undefined175.46 M undefined
2027e587.36 M undefined74.6 M undefined118.19 M undefined
2026e459.68 M undefined63.03 M undefined46.89 M undefined
2025e357.13 M undefined22.66 M undefined8.56 M undefined
2024e269.65 M undefined-2.24 M undefined-18.25 M undefined
2023202.09 M undefined-36.11 M undefined-61.69 M undefined
2022148.6 M undefined-59.5 M undefined-74.4 M undefined
202199.7 M undefined-63.6 M undefined-46.8 M undefined
202056.5 M undefined-68.7 M undefined-163 M undefined
201934.9 M undefined-94.7 M undefined-90 M undefined
20180 undefined-35.6 M undefined-46.9 M undefined
20170 undefined-11.7 M undefined-4.5 M undefined
20160 undefined-20 M undefined-20.1 M undefined
20150 undefined-31 M undefined-31.1 M undefined

Evolus Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000345699148202269357459587702841
-----64.7176.7949.4936.4933.1732.7128.5727.8919.5919.80
----76.4767.8656.5762.1669.3152.0439.2230.5023.8519.9416.65
000026385692140000000
-31-20-4-46-90-163-46-74-61-18846118175149
--35.48-80.001,050.0095.6581.11-71.7860.87-17.57-70.49-144.44475.00156.5248.31-14.86
23.623.623.624.428.233.749.856.156.92000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Evolus Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Evolus is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
00093.2129.8107.6146.353.962.84
000010.79.714.722.430.53
000000000
00006.43.41.818.911
40.20.21.25.3716.15.68.06
40.20.294.4152.2127.7178.9100.8112.42
000054.74.14.67.85
000000000
000000000
56.156.156.156.159.655.350.648.647.11
21.221.221.221.221.221.221.221.221.21
002.10.22.40.22.82.80.41
77.377.379.477.588.281.478.777.276.58
81.377.579.6171.9240.4209.1257.6178189
                 
000000000
58.759.70207.4292.5303.1504.8516.1538.72
-46.7-66.8-75.5-123-213.1-376.1-422.9-497.3-558.98
0000000-0.3-0.43
000000000
12-7.1-75.584.479.4-7381.918.5-20.69
0.22.90.41.65.89.66.18.94.27
1.70.713.715.270.738.322.124.16
00003.56.513.215.519.86
46.259.872.60019.1000
00138.70074.4000
48.163.4212.75.324.5180.357.646.548.29
00016.991.540.571.271.9120.36
21.221.21515.100000.03
00050.245.161.246.741.141.01
21.221.21582.2136.6101.7117.9113161.4
69.384.6227.787.5161.1282175.5159.5209.69
81.377.5152.2171.9240.5209257.4178189
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Evolus provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Evolus's financial health and stability.

Assets

Evolus's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Evolus must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Evolus after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Evolus's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
-31-20-4-46-90-163-46-74-61
000047535
00-60-150000
-75-22-2035-11-34-5
310253773283044
0000570812
000000000
-36-13-13-25-93-57-33-84-34
0000-4-30-2-1
0000-23124-2-1
0000-1815500
000000000
361314-37239-24050
0001247301100
3613131181333873-444
00-1-1-12-185-4-5
000000000
0009316-743-928
-36.38-13.27-13.22-25.68-97.95-61.01-34.36-87.85-35.64
000000000

Evolus stock margins

The Evolus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Evolus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Evolus.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Evolus's sales revenue. A higher gross margin percentage indicates that the Evolus retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Evolus's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Evolus's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Evolus's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Evolus. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Evolus's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Evolus Margin History

Evolus Gross marginEvolus Profit marginEvolus EBIT marginEvolus Profit margin
2029e69.54 %23.55 %17.81 %
2028e69.54 %18.72 %24.98 %
2027e69.54 %12.7 %20.12 %
2026e69.54 %13.71 %10.2 %
2025e69.54 %6.34 %2.4 %
2024e69.54 %-0.83 %-6.77 %
202369.54 %-17.87 %-30.52 %
202262.38 %-40.04 %-50.07 %
202156.27 %-63.79 %-46.94 %
202067.61 %-121.59 %-288.5 %
201977.08 %-271.35 %-257.88 %
201869.54 %0 %0 %
201769.54 %0 %0 %
201669.54 %0 %0 %
201569.54 %0 %0 %

Evolus Stock Sales Revenue, EBIT, Earnings per Share

The Evolus earnings per share therefore indicates how much revenue Evolus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Evolus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Evolus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Evolus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Evolus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Evolus Revenue, EBIT and net profit per share

DateEvolus Sales per ShareEvolus EBIT per shareEvolus Earnings per Share
2029e13.28 undefined0 undefined2.37 undefined
2028e11.09 undefined0 undefined2.77 undefined
2027e9.28 undefined0 undefined1.87 undefined
2026e7.26 undefined0 undefined0.74 undefined
2025e5.64 undefined0 undefined0.14 undefined
2024e4.26 undefined0 undefined-0.29 undefined
20233.55 undefined-0.63 undefined-1.08 undefined
20222.65 undefined-1.06 undefined-1.33 undefined
20212 undefined-1.28 undefined-0.94 undefined
20201.68 undefined-2.04 undefined-4.84 undefined
20191.24 undefined-3.36 undefined-3.19 undefined
20180 undefined-1.46 undefined-1.92 undefined
20170 undefined-0.5 undefined-0.19 undefined
20160 undefined-0.85 undefined-0.85 undefined
20150 undefined-1.31 undefined-1.32 undefined

Evolus business model

Evolus Inc is an innovative biotechnology company based in Irvine, California, specializing in the development and distribution of aesthetic treatments. The company was founded in 2012 and has quickly become a market leader in the industry. Evolus is one of the most popular companies on Eulerpool.com.

Evolus SWOT Analysis

Strengths

Evolus Inc has a diverse and dedicated team of experienced professionals, allowing for a wide range of expertise and perspectives.

The company's flagship product, Jeuveau, has been approved by the FDA and offers a competitive advantage in the aesthetics market.

Evolus Inc has established strong relationships with key stakeholders, including healthcare professionals, medical spas, and distributors, enhancing its market presence.

Weaknesses

Evolus Inc operates in a highly competitive industry, with well-established competitors, which may pose challenges in gaining market share.

The company heavily relies on the success of Jeuveau, which could result in increased vulnerability to market fluctuations or potential product failures.

Evolus Inc may face regulatory hurdles or legal issues that could delay product launches or negatively impact its reputation.

Opportunities

Evolus Inc can leverage the growing demand for minimally invasive aesthetics procedures, presenting an opportunity for market expansion.

The company can explore partnerships or collaborations with established players in the industry to further enhance its product portfolio and reach.

Evolus Inc has the potential to expand its geographic presence by targeting new markets and regions with untapped growth potential.

Threats

Evolus Inc faces regulatory risks, such as changes in government regulations or requirements, which could impact its ability to operate or market its products.

The company is susceptible to the emergence of new competitive products or technologies, which may challenge its market positioning.

Evolus Inc must navigate potential economic downturns or recessions, which could affect consumer spending power and demand for aesthetic treatments.

Evolus Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Evolus Revenue by Segment

Segmente20232022202120202019
Product revenue, net199.72 M USD146.59 M USD98.97 M USD55.8 M USD34.24 M USD
Service revenue2.36 M USD2.02 M USD702,000 USD738,000 USD688,000 USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Evolus Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Evolus historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Evolus shares outstanding

The number of shares was Evolus in 2024 — This indicates how many shares 56.919 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Evolus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Evolus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Evolus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Evolus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Evolus.

Evolus latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.1 -0.16  (-60.8 %)2024 Q3
6/30/2024-0.05 -0.04  (24.53 %)2024 Q2
3/31/2024-0.11 -0.09  (15.97 %)2024 Q1
12/31/2023-0.07 -0.12  (-75.7 %)2023 Q4
9/30/2023-0.18 -0.16  (9.86 %)2023 Q3
6/30/2023-0.2 -0.19  (4.19 %)2023 Q2
3/31/2023-0.15 -0.15  (0.86 %)2023 Q1
12/31/2022-0.15 -0.14  (7.16 %)2022 Q4
9/30/2022-0.28 -0.28  (0.89 %)2022 Q3
6/30/2022-0.25 -0.28  (-13.13 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Evolus stock

Eulerpool World ESG Rating (EESG©)

30/ 100

🌱 Environment

30

👫 Social

45

🏛️ Governance

13

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees70
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Evolus shareholders

%
Name
Stocks
Change
Date
9.08686 % Perceptive Advisors LLC5,753,79806/30/2024
7.65540 % Tang Capital Management, LLC4,847,399700,0006/30/2024
5.54628 % BlackRock Institutional Trust Company, N.A.3,511,907649,9946/30/2024
5.34006 % Medy Tox Inc3,381,326-1,690,66310/16/2023
4.95399 % Daewoong Pharma3,136,86904/19/2024
4.69863 % The Vanguard Group, Inc.2,975,17379,7056/30/2024
4.59705 % Nantahala Capital Management, LLC2,910,84906/30/2024
3.87203 % Great Point Partners, LLC2,451,7721,7726/30/2024
3.42355 % Caligan Partners, LP2,167,790278,9096/30/2024
2.61783 % Stonepine Capital Management, LLC1,657,611-1,016,7456/30/2024
1
2
3
4
5
...
10

Evolus Executives and Management Board

Mr. David Moatazedi

(45)
Evolus President, Chief Executive Officer, Director (since 2018)
Compensation 3.6 M

Ms. Sandra Beaver

(45)
Evolus Chief Financial Officer
Compensation 1.83 M

Dr. Rui Avelar

(61)
Evolus Chief Medical Officer, Head of Research and Development
Compensation 1.26 M

Mrs. Brady Stewart

(47)
Evolus Independent Director
Compensation 275,000

Mr. Vikram Malik

(60)
Evolus Non-Executive Chairman of the Board, Independent Director (since 2018)
Compensation 247,698
1
2
3

Most common questions regarding Evolus

What values and corporate philosophy does Evolus represent?

Evolus Inc represents a commitment to innovation, integrity, and patient satisfaction. As a pharmaceutical company specializing in aesthetic medicine, Evolus aims to provide advanced solutions that enhance the lives of patients. The company values scientific excellence and invests in rigorous research and development to deliver high-quality products. With a customer-centric approach, Evolus fosters meaningful relationships with healthcare professionals and strives to meet the evolving needs of patients worldwide.

In which countries and regions is Evolus primarily present?

Evolus Inc primarily operates in the United States.

What significant milestones has the company Evolus achieved?

Evolus Inc has achieved several significant milestones. Firstly, the company received FDA approval in 2019 for its revolutionary product Jeuveau, a wrinkle treatment. This approval marked a major breakthrough for Evolus Inc, as it became the first and only neurotoxin alternative to Botox in the United States. Additionally, the company successfully secured a collaboration agreement with Daewoong Pharmaceutical to commercialize Jeuveau in key Asian markets, further expanding its global reach. Evolus Inc's continuous efforts in research and development have enabled it to provide innovative aesthetic solutions, positioning the company as a leader in the industry.

What is the history and background of the company Evolus?

Evolus Inc is a renowned pharmaceutical company specializing in aesthetic medicine. Established in 2012, Evolus has quickly made a name for itself in the industry. The company is focused on developing and commercializing innovative products for aesthetic procedures, with a primary emphasis on neurotoxins. Evolus is widely recognized for its flagship product Jeuveau™, a revolutionary wrinkle treatment approved by the FDA. Jeuveau™ competes directly with other well-known aesthetic brands, providing consumers with a broader range of choices. With a strong commitment to excellence and continuous innovation, Evolus Inc has emerged as a key player in the field of aesthetics.

Who are the main competitors of Evolus in the market?

The main competitors of Evolus Inc in the market are major players in the medical aesthetics industry, including Allergan plc and Merz Pharma Group. These companies also manufacture and distribute aesthetic treatments and products, such as Botox and dermal fillers, which compete with Evolus' Jeuveau. Allergan, as a subsidiary of AbbVie Inc, remains a strong competitor in this segment, given its well-established brand reputation and extensive customer base. On the other hand, Merz Pharma Group, a global leader in the aesthetics market, offers its own range of injectable aesthetic products and medical devices, posing a competitive challenge to Evolus Inc.

In which industries is Evolus primarily active?

Evolus Inc is primarily active in the pharmaceutical and healthcare industries.

What is the business model of Evolus?

The business model of Evolus Inc. revolves around developing and commercializing prescription aesthetic products for healthcare professionals and their patients. Evolus primarily focuses on providing innovative products for facial aesthetics, with a key emphasis on its flagship brand, Jeuveau®. Jeuveau® is a prescription medicine that is injected into facial muscles to temporarily improve the appearance of moderate to severe glabellar lines (frown lines between the eyebrows). By offering safe and effective aesthetic solutions, Evolus Inc. aims to meet the growing demand for non-surgical treatments and contribute to the success of healthcare professionals and the satisfaction of their patients.

What is the P/E ratio of Evolus 2025?

The Evolus P/E ratio is 65.63.

What is the P/S ratio of Evolus 2025?

The Evolus P/S ratio is 1.57.

What is the Quality Investing of Evolus?

The Quality Investing for Evolus is 4/10.

What is the revenue of Evolus 2025?

The expected Evolus revenue is 357.13 M USD.

How high is the profit of Evolus 2025?

The expected Evolus profit is 8.56 M USD.

What is the business model of Evolus

Evolus Inc is an American company based in California that specializes in the development, manufacturing, and marketing of prescription dermatological products. The business model primarily focuses on selling products and services in the beauty and aesthetic medicine fields, with a focus on developing technologies that naturally enhance the appearance of skin and face. Evolus Inc offers a wide range of products and services. In 2019, the company introduced its first and only product so far, Jeuveau, to the market. Jeuveau is an injectable botulinum toxin primarily used for treating glabellar lines or "frown lines" between the eyebrows. It is a cost-effective and effective alternative to the botulinum toxin preparations already available on the market. Recently, Evolus has also focused on other products and technologies to expand its offering. One such technology is the Heatwave technology, which provides a non-invasive way to stimulate collagen production in the face. It uses targeted heat energy to tighten the skin, reduce wrinkles, and overall improve the appearance of the face. Evolus Inc has also partnered with Kalos Therapeutics to develop a broader range of products for aesthetic dermatological therapy. This partnership includes the development of drug combinations that specifically target the causes of acne, rosacea, and other skin conditions. In terms of marketing and sales, Evolus primarily relies on direct sales. The products are sold on the company's website and in selected medical facilities. An important target audience are doctors, plastic surgeons, and dermatologists, to whom the company offers training and education to ensure the proper use of the products. In summary, Evolus Inc's business model is primarily based on the development and marketing of innovative skincare products and aesthetic procedures for the beauty industry. The company aims to develop cost-effective and effective alternatives to the products already available on the market and expand its presence in the industry. With its wide range of products and technologies and its focus on direct distribution channels, Evolus is well positioned to continue attracting the interest of customers and investors.

What is the Evolus dividend?

Evolus pays a dividend of 0 USD distributed over payouts per year.

How often does Evolus pay dividends?

The dividend cannot currently be calculated for Evolus or the company does not pay out a dividend.

What is the Evolus ISIN?

The ISIN of Evolus is US30052C1071.

What is the Evolus WKN?

The WKN of Evolus is A2JDYX.

What is the Evolus ticker?

The ticker of Evolus is EOLS.

How much dividend does Evolus pay?

Over the past 12 months, Evolus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Evolus is expected to pay a dividend of 0 USD.

What is the dividend yield of Evolus?

The current dividend yield of Evolus is .

When does Evolus pay dividends?

Evolus pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Evolus?

Evolus paid dividends every year for the past 0 years.

What is the dividend of Evolus?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Evolus located?

Evolus is assigned to the 'Health' sector.

Wann musste ich die Aktien von Evolus kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Evolus from 1/15/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/15/2025.

When did Evolus pay the last dividend?

The last dividend was paid out on 1/15/2025.

What was the dividend of Evolus in the year 2024?

In the year 2024, Evolus distributed 0 USD as dividends.

In which currency does Evolus pay out the dividend?

The dividends of Evolus are distributed in USD.

All fundamentals about Evolus

Our stock analysis for Evolus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evolus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.